Loading...

Brilliant Violet 785™ anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_BV785_061412
C57BL/6 mouse splenocytes were stained with CD3 PE and CD4 (clone RM4-5) Brilliant Violet 785™.
  • RM4-5_BV785_061412
    C57BL/6 mouse splenocytes were stained with CD3 PE and CD4 (clone RM4-5) Brilliant Violet 785™.
See Brilliant Violet 785™ spectral data
Cat # Size Price Quantity Check Availability Save
100551 125 µL 168€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100552 50 µg 219€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  2. Schulthess J et al. 2019. Immunity. 50(2):432-445 . PubMed
  3. Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed
  4. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  5. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
  6. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  7. Grizotte–Lake M, et al. 2018. Immunity. 49:1103. PubMed
  8. Sophie Thiemann et al. 2017. Cell host & microbe. 21(6):682-694 . PubMed
  9. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  10. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  11. Chauveau A, et al. 2020. Immunity. 52:794. PubMed
  12. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  13. Jin C, et al. 2019. Cell. 176:998. PubMed
  14. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  15. Cillo AR, et al. 2020. Immunity. 52(1):183-199.e9.. PubMed
  16. McGinley AM, et al. 2020. Immunity. 52(2):342-356. PubMed
  17. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
  18. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
  19. Pérol L, et al. 2016. Nat Commun. 7:13027. PubMed
  20. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  21. Koivisto CS, et al. 2020. Neoplasia. 1.252777778. PubMed
  22. Dubois V, et al. 2021. NPJ Vaccines. 6:06. PubMed
  23. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  24. Yun H, et al. 2020. Immunity. 53(5):1050-1062.e5. PubMed
  25. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  26. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  27. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  28. Yilmaz B, et al. 2021. Cell Host Microbe. 29(4):650-663.e9. PubMed
  29. Lu SX, et al. 2021. Cell. . PubMed
  30. Dupraz L, et al. 2021. Cell Reports. 36(1):109332. PubMed
  31. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  32. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  33. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  34. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  35. Chiang HY, et al. 2022. Nat Commun. 13:874. PubMed
  36. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  37. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  38. Francian A, et al. 2021. J Drug Target. 29:754. PubMed
  39. Kim S, et al. 2021. Elife. 10:. PubMed
  40. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  41. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  42. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  43. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  44. Kiani Shabestari S, et al. 2022. Cell Rep. 39:110961. PubMed
  45. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  46. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  47. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
RRID
AB_11218992 (BioLegend Cat. No. 100551)
AB_2563053 (BioLegend Cat. No. 100552)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 2    Revision Date: 01/29/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account